Phenomix's DPP-4 inhibitor meets goal in Phase III diabetes trial
This article was originally published in Scrip
Executive Summary
Phenomix's DPP-4 inhibitor dutogliptin has met its primary endpoint in a Phase III trial in patients with type 2 diabetes, top-line results show. However, despite the positive data, Forest Laboratories has decided to terminate its collaboration with Phenomix to develop dutogliptin.